NBS for SMA was begun on 28 February 2022 and included a qPCR screening assay to detect the absence of SMN1 exon 7, which was multiplexed with an already established SCID qPCR assay allowing for a smooth cost-effective implementation. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.